Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Significant Drop in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 26,300 shares, a decrease of 27.7% from the November 30th total of 36,400 shares. Based on an average daily trading volume, of 321,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.9% of the company’s stock are sold short.

Salarius Pharmaceuticals Trading Up 0.4 %

Salarius Pharmaceuticals stock traded up $0.01 during trading hours on Friday, reaching $1.67. 33,064 shares of the company were exchanged, compared to its average volume of 703,819. Salarius Pharmaceuticals has a 12 month low of $1.22 and a 12 month high of $7.20. The stock has a 50-day moving average of $1.51 and a 200 day moving average of $1.86. The firm has a market cap of $2.41 million, a price-to-earnings ratio of -0.20 and a beta of 0.92.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.